Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Loss of Expression and Aberrant Methylation of the CDH1 (E-cadherin) Gene in Breast Cancer Patients from Kashmir

  • Asiaf, Asia (Department of Biochemistry, Faculty of Biological Science, University of Kashmir) ;
  • Ahmad, Shiekh Tanveer (Clarke H. Smith Brain Tumour Centre, University of Calgary) ;
  • Aziz, Sheikh Aejaz (Department of Medical Oncology, Sher-I-Kashmir Institute of Medical Sciences) ;
  • Malik, Ajaz Ahmad (Department Of General Surgery, Sher-I-Kashmir Institute of Medical Sciences) ;
  • Rasool, Zubaida (Department Of Pathology, Sher-I-Kashmir Institute of Medical Sciences) ;
  • Masood, Akbar (Department of Biochemistry, Faculty of Biological Science, University of Kashmir) ;
  • Zargar, Mohammad Afzal (Department of Biochemistry, Faculty of Biological Science, University of Kashmir)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Aberrant promoter hypermethylation has been recognized in human breast carcinogenesis as a frequent molecular alteration associated with the loss of expression of a number of key regulatory genes and may serve as a biomarker. The E-cadherin gene (CDH1), mapping at chromosome 16q22, is an intercellular adhesion molecule in epithelial cells, which plays an important role in establishing and maintaining intercellular connections. The aim of our study was to assess the methylation pattern of CDH1 and to correlate it with the expression of E-cadherin, clinicopathological parameters and hormone receptor status in breast cancer patients of Kashmir. Materials and Methods: Methylation specific PCR (MSP) was used to determine the methylation status of CDH1 in 128 invasive ductal carcinomas (IDCs) paired with the corresponding normal tissue samples. Immunohistochemistry was used to study the expression of E-cadherin, ER and PR. Results: CDH1 hypermethylation was detected in 57.8% of cases and 14.8% of normal adjacent controls. Reduced levels of E-cadherin protein were observed in 71.9% of our samples. Loss of E-cadherin expression was significantly associated with the CDH1 promoter region methylation (p<0.05, OR=3.48, CI: 1.55-7.79). Hypermethylation of CDH1 was significantly associated with age at diagnosis (p=0.030), tumor size (p=0.008), tumor grade (p=0.024) and rate of node positivity or metastasis (p=0.043). Conclusions: Our preliminary findings suggest that abnormal CDH1 methylation occurs in high frequencies in infiltrating breast cancers associated with a decrease in E-cadherin expression. We found significant differences in tumor-related CDH1 gene methylation patterns relevant to tumor grade, tumor size, nodal involvement and age at diagnosis of breast tumors, which could be extended in future to provide diagnostic and prognostic information.

Keywords

References

  1. Acs G, Lawton TJ, Rebbeck TR, et al (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Path, 115, 85-98. https://doi.org/10.1309/FDHX-L92R-BATQ-2GE0
  2. Andrews JL, Kim AC, Hens JR (2012). The role and function of cadherins in the mammary gland. Breast Cancer Res, 14, 203-13.
  3. Baylin SB, Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet, 16, 168-74. https://doi.org/10.1016/S0168-9525(99)01971-X
  4. Berx G, Cleton-Jansen AM, Nollet F, et al (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J, 14, 6107.
  5. Brock MV, Gou M, Akiyama Y, et al (2003). Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin cancer res, 9, 2912-9.
  6. Caldeira JRF, Prando EC, Quevedo FC, et al (2006). CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC cancer, 6, 48. https://doi.org/10.1186/1471-2407-6-48
  7. Cavallaro U, Christofori G (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer, 4, 118-32. https://doi.org/10.1038/nrc1276
  8. Debies MT, Welch DR (2001). Genetic basis of human breast cancer metastasis. J Mammary Gland Biol Neoplasia, 6, 441-51. https://doi.org/10.1023/A:1014739131690
  9. Elledge RM, Green S, Pugh R, et al (2000). Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group study. Int J Cancer, 89, 111-7. https://doi.org/10.1002/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W
  10. Fisher B, Redmond C, Brown A, et al (1983). Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol, 1, 227-41.
  11. Graff JR, Gabrielson E, Fujii H, et al (2000). Methylation patterns of the E-cadherin 5'- CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem, 275, 2727-32. https://doi.org/10.1074/jbc.275.4.2727
  12. Graff JR, Herman JG, Lapidus RG, et al (1995). E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res, 55, 5195-9.
  13. Hajra KM, Ji X, Fearon ER (1999). Extinction of E-cadherin expression in breast cancer via a dominant repression pathway acting on proximal promoter elements. Oncogene, 18.
  14. Harvey JM, Clark GM, Osborne CK, et al (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol, 17, 1474-.
  15. Hennig G, Lowrick O, Birchmeier W, et al (1996). Mechanisms identified in the transcriptional control of epithelial gene expression. J Biol Chem, 271, 595-602. https://doi.org/10.1074/jbc.271.1.595
  16. Hirohashi S (1998). Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Path, 153, 333-9. https://doi.org/10.1016/S0002-9440(10)65575-7
  17. Hu X-C, Loo WTY, Chow LWC (2002). E-cadherin promoter methylation can regulate its expression in invasive ductal breast cancer tissue in Chinese woman. Life sci, 71, 1397-404. https://doi.org/10.1016/S0024-3205(02)01843-X
  18. Issa JP, Ahuja N (2000). Aging, methylation and cancer. Histol Histopathol, 15, 835-42.
  19. Kanai Y, Oda T, Tsuda H, et al (1994). Point mutation of the ecadherin gene in invasive lobular carcinoma of the breast. Cancer Sci, 85, 1035-9. https://doi.org/10.1111/j.1349-7006.1994.tb02902.x
  20. Kowalski PJ, Rubin MA, Kleer CG (2003). E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res, 5, 217-22. https://doi.org/10.1186/bcr651
  21. Li S, Rong M, Iacopetta B (2006). DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett, 237, 272-80. https://doi.org/10.1016/j.canlet.2005.06.011
  22. Lo P-K, Sukumar S (2008). Epigenomics and breast cancer. Pharmacogenomics.
  23. Lombaerts M, Middeldorp JW, van der Weide E, et al (2004). Infiltrating leukocytes confound the detection of E-cadherin promoter methylation in tumors. Biochem Bioph Res Co, 319, 697-704. https://doi.org/10.1016/j.bbrc.2004.05.041
  24. Mir MR, Shabir N, Wani KA, et al (2012). Association between p16, hMLH1 and E-cadherin promoter hypermethylation and intake of local hot salted tea and sun-dried foods in Kashmiris with gastric tumors. Asian Pac J Cancer Prev, 13, 181-6. https://doi.org/10.7314/APJCP.2012.13.1.181
  25. Nass SJ, Herman JG, Gabrielson E, et al (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5 CpG islands increases with malignant progression in human breast cancer. Cancer Res, 60, 4346-8.
  26. Oka H, Shiozaki H, Kobayashi K, et al (1992). Correlation between E-cadherin expression and metastasis in human breast cancer: preliminary report. Nihon Geka Gakkai zasshi, 93, 105.
  27. Overduin M, Harvey TS, Bagby S, et al (1995). Solution structure of the epithelial cadherin domain responsible for selective cell adhesion. Science, 267, 386-9. https://doi.org/10.1126/science.7824937
  28. Peinado H, Ballestar E, Esteller M, et al (2004). Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol, 24, 306-19. https://doi.org/10.1128/MCB.24.1.306-319.2004
  29. Prasad CP, Mirza S, Sharma G, et al (2008). Epigenetic alterations of CDH1 and APC genes: Relationship with activation of Wnt/beta- catenin pathway in invasive ductal carcinoma of breast. Life Sci, 83, 318-25. https://doi.org/10.1016/j.lfs.2008.06.019
  30. Raish M, Dhillon VS, Ahmad A, et al (2009). Promoter hypermethylation in tumor suppressing genes p16 and FHIT and their relationship with estrogen receptor and progesterone receptor status in breast cancer patients from Northern India. Transl Oncol, 2, 264. https://doi.org/10.1593/tlo.09148
  31. Ronneberg JA, Fleischer T, Solvang HK, et al Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. Mol Oncol, 5, 61-76.
  32. Rose C, Andersen K, Mouridsen H, et al (1985). Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. The Lancet, 325, 16-9. https://doi.org/10.1016/S0140-6736(85)90966-3
  33. Sadot E, Simcha I, Shtutman M, et al (1998). Inhibition of $\beta$-catenin-mediated transactivation by cadherin derivatives. Proc Natl Acad Sci USA, 95, 15339-44. https://doi.org/10.1073/pnas.95.26.15339
  34. Sarrio D, Perez-Mies B, Hardisson D, et al (2004). Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene, 23, 3272-83. https://doi.org/10.1038/sj.onc.1207439
  35. Sebova K, Zmetakova I, Bella V, et al (2011). RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Epidemiol Biomarkers Prev, 10, 13-26.
  36. Shargh SA, Sakizli M, Farajnia S, et al (2011). Evaluation of methylation pattern in promoter region of E-cadherin gene and its relation to tumor grade and stage in breast cancer. Afr J Biotechnol, 10, 1745-51.
  37. Shinozaki M, Hoon DSB, Giuliano AE, et al (2005). Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res, 11, 2156-62. https://doi.org/10.1158/1078-0432.CCR-04-1810
  38. Sofi GN, Sofi JN, Nadeem R, et al (2012). Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. Asian Pac J Cancer Prev, 13, 5047-52. https://doi.org/10.7314/APJCP.2012.13.10.5047
  39. Syeed N, Husain SA, Abdullah S, et al (2010). Caveolin-1 promotes mammary tumorigenesis: mutational profile of the Kashmiri population. Asian Pac J Cancer Prev, 11, 689-96.
  40. Szyf M, Pakneshan P, Rabbani SA (2004). DNA methylation and breast cancer. Bioche Pharmacol, 68, 1187-97. https://doi.org/10.1016/j.bcp.2004.04.030
  41. Tamura G, Yin J, Wang S, et al (2000). E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst, 92, 569-73. https://doi.org/10.1093/jnci/92.7.569
  42. Tao MH, Shields PG, Nie J, et al (2009). DNA hypermethylation and clinicopathological features in breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. Breast Cancer Res Tr, 114, 559-68. https://doi.org/10.1007/s10549-008-0028-z
  43. Valavaara R, Tuominen J, Johansson R (1990). Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer, 66, 2264-9. https://doi.org/10.1002/1097-0142(19901201)66:11<2264::AID-CNCR2820661103>3.0.CO;2-9
  44. Vos CB, Cleton-Jansen AM, Berx G, et al (1997). E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer, 76, 1131. https://doi.org/10.1038/bjc.1997.523
  45. Wani SQ, Khan T, Wani SY, et al (2012). Clinicoepidemiological analysis of female breast cancer patients in Kashmir. J Can Res Ther, 8, 389. https://doi.org/10.4103/0973-1482.103518
  46. Xiong H-L, Liu X-Q, Sun A-H, et al (2013). Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pac J Cancer Prev, 14, 3139-42. https://doi.org/10.7314/APJCP.2013.14.5.3139
  47. Yang X, Yan L, Davidson NE (2001). DNA methylation in breast cancer. Endocr-Relat Cancer, 8, 115-27. https://doi.org/10.1677/erc.0.0080115
  48. Yoder BJ, Wilkinson EJ, Massoll NA (2007). Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J, 13, 172-9. https://doi.org/10.1111/j.1524-4741.2007.00393.x
  49. Yoshida R, Kimura N, Harada Y, et al (2001). The loss of E-cadherin, $\alpha$ and $\beta$-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol, 18, 513.
  50. Yuan Y-L, Wang Y-M, Liu H, et al (2012). Aberrant expression of e-cadherin in lung tissues of patients with probable lung cancer. Asian Pac J Cancer Prev, 13, 5149-53. https://doi.org/10.7314/APJCP.2012.13.10.5149
  51. Zheng, Shi-Ying, Hou, et al (2012). Clinical outcomes of downregulation of E-cadherin gene expression in non-small cell lung cancer. Asian Pac J Cancer Prev, 13, 1557-61. https://doi.org/10.7314/APJCP.2012.13.4.1557

Cited by

  1. The Identification of Specific Methylation Patterns across Different Cancers vol.10, pp.3, 2015, https://doi.org/10.1371/journal.pone.0120361
  2. Legumain Protein as a Potential Predictive Biomarker for Asian Patients with Breast Carcinoma vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10773
  3. Aberrant Methylation of RASSF1A gene Contribute to the Risk of Renal Cell Carcinoma: a Meta-Analysis vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4665
  4. Promoter Methylation Status of Two Novel Human Genes, UBE2Q1 and UBE2Q2, in Colorectal Cancer: a New Finding in Iranian Patients vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8247
  5. Breast cancer risk in relation to TP53 codon 72 and CDH1 gene polymorphisms in the Bangladeshi women vol.37, pp.6, 2016, https://doi.org/10.1007/s13277-015-4612-7
  6. Promoter methylation and expression of CDH1 and susceptibility and prognosis of eyelid squamous cell carcinoma vol.37, pp.7, 2016, https://doi.org/10.1007/s13277-016-4851-2
  7. β-Catenin is important for cancer stem cell generation and tumorigenic activity in nasopharyngeal carcinoma vol.48, pp.3, 2016, https://doi.org/10.1093/abbs/gmv134
  8. Chromosome 16q genes CDH1, CDH13 and ADAMTS18 are correlated and frequently methylated in human lymphoma vol.12, pp.5, 2016, https://doi.org/10.3892/ol.2016.5116
  9. Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach pp.1532-2807, 2018, https://doi.org/10.1007/s12253-018-0500-y